Rituximab Twice Weekly for Refractory Thrombotic Thrombocytopenic Purpura in a Critically Ill Patient with Acute Respiratory Distress Syndrome

Rituximab Twice Weekly for Refractory Thrombotic Thrombocytopenic Purpura in a Critically Ill Patient with Acute Respiratory Distress Syndrome

Thrombotic thrombocytopenic purpura (TTP) is a rare, serious, life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and hypercoagulability. The etiology is a deficiency of ADAMTS13 which is usually caused by acquired antibodies. Plasma exchange and steroids i...

Full description

Bibliographic Details
Main Authors: Bahjat Azrieh, Arwa Alsaud, Khaldun Obeidat, Amr Ashour, Seham Elebbi, Shehab F. Mohamed, Mohamed Adel Abdelaty, Abdelraouf Akkari, Abdurrahman Ali Elbuzidi, Mohamed A. Yassin
Format: Article
Language:English
Published: Karger Publishers 2020-02-01
Series:Case Reports in Oncology
Subjects:
thrombotic thrombocytopenic purpura
thrombocytopenia
platelet disorder
refractory disease
relapse
rituximab
Online Access:https://www.karger.com/Article/FullText/505236

Internet

https://www.karger.com/Article/FullText/505236

Similar Items